

Coexistence of Asymptomatic Allergic Bronchopulmonary Aspergillosis and Active Pulmonary Tuberculosis: Case Report

Qingqing Jia^{1,2,*}, Lian Wang^{1,2,*}, Xiang Tong^{1,2}, Jibo Sun^{1,2}, Hong Fan^{1,2}

¹Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China; ²State Key Laboratory of Respiratory Health and Multimorbidity, Sichuan University, Chengdu, 610041, People's Republic of China

*These authors contributed equally to this work

Correspondence: Hong Fan, Email fanhong@scu.edu.cn

Abstract: We present a rare case of asymptomatic allergic bronchopulmonary aspergillosis (ABPA) concurrent with active pulmonary tuberculosis. Allergic bronchopulmonary aspergillosis is an immunological pulmonary disorder characterized by hypersensitivity to *Aspergillus fumigatus*, while pulmonary tuberculosis (PTB) is a complex infection caused by *Mycobacterium tuberculosis* (MTB). The association between pulmonary tuberculosis infections and *Aspergillus* infections remains a fascinating area of inquiry. A 26-year-old female patient exhibited no symptoms. However, her initial chest computed tomography revealed bronchiectasis with high-attenuation mucus plugs in the upper lobes, peripheral lung atelectasis, and a tree-in-bud pattern. To obtain a clear diagnosis, she visited multiple hospitals and incurred substantial time and financial costs. Active tuberculosis was initially confirmed using specialized detection methods, including metagenomic next-generation sequencing and Xpert MTB/RIF analysis of bronchoalveolar lavage fluid. Subsequent pathological biopsy and *Aspergillus*-specific antibody tests further confirmed the diagnosis of allergic bronchopulmonary aspergillosis combined with active tuberculosis. Following twelve months of antituberculosis therapy, an avoidable surgery, and three months of oral glucocorticoid treatment, the patient's lung lesions showed significant resolution. This case provides valuable insights into the clinical diagnosis and management of these two distinct infectious diseases.

Keywords: allergic bronchopulmonary aspergillosis, tuberculosis, coexistence, asymptomatic, case report

Introduction

Allergic bronchopulmonary aspergillosis is an immunological pulmonary disorder characterized by hypersensitivity to *Aspergillus fumigatus*, which colonizes the airways primarily in patients with chronic lung disease, notably asthma or cystic fibrosis.¹ Pulmonary tuberculosis is a complex pulmonary infection caused by *Mycobacterium tuberculosis*. Patients with a history of PTB often develop various complications, including bronchiectasis and chronic pulmonary aspergillosis, collectively termed post-tubercular lung diseases (PTLD).² The prevalence of ABPA in PTLD patients is approximately 2.37%.³ However, simultaneous diagnosis of active PTB and ABPA is much more seldom documented.

Case Report

A 26-year-old woman presented with incidental findings of bilateral lung lesions on a Chest X-ray during a health examination. She remained asymptomatic, with no fever, dry cough, wheezing, or weight loss, and denied any previous respiratory diseases. A CT scan showed bronchiectasis with intraluminal high-attenuation mucus plugs in the right upper lobe, accompanied by peripheral lung atelectasis and tree-in-bud appearance. Additionally, a solid nodule was noted in the lingual segment of the left upper lobe (Figure 1A).

Laboratory findings previously in the local hospital revealed an elevated eosinophil count (EOS, $0.91 \times 10^9/L$) and EOS% (17.6%), along with a total serum immunoglobulin E (IgE) level exceeding 6000 ng/mL (normal <165 IU/mL).




Figure 1 High-resolution CT scan images showing various stages of pulmonary changes. **(A)** Bronchiectasis with intraluminal high-attenuation mucus in the right upper lobe, associated with peripheral lung atelectasis and a tree-in-bud appearance, along with a solid nodule in the lingual segment of the left upper lobe. **(B)** Partial absorption of bilateral upper lung lesions after 8 months of anti-tuberculosis therapy, with a reduction in the size of the lesions. **(C)** A newly developed solid mass in the lingual segment of the left upper lobe, observed 4 months post-surgery, indicating possible post-surgical changes or recurrence. **(D)** Marked reduction in the size of the solid mass in the left upper lobe lingual segment after six weeks of steroid treatment, suggesting a significant therapeutic response.

The purified protein derivative (PPD) skin test was positive (++). The sputum smear, acid-fast staining, and sputum culture were negative. Further assessments excluded malignancies and autoimmune disorders such as ANCA-associated vasculitis. Ultimately, metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid (BALF) collected from the right upper lobe revealed the presence of *Mycobacterium tuberculosis* (reads of 23). Additionally, the Xpert MTB/RIF analysis of BALF yielded a positive result, indicating sensitivity to rifampicin, streptomycin, ethambutol, and second-line injectable drugs, confirming the diagnosis of active pulmonary tuberculosis, though both the acid-fast stain and MTB culture of the BALF were negative.

Consequently, the patient underwent a 12-month course of standard anti-tuberculosis therapy (RPT/INH/EMB/PZA with an initial phase for 2 months, followed by a maintenance phase for 10 months with RPT/INH). Follow-up radiological assessments demonstrated gradual partial absorption of bilateral upper lung lesions (Figure 1B). Due to concerns about incomplete lesion resolution and the risk of tuberculosis recurrence, bilateral upper lung segmentectomy surgery was performed following a thorough evaluation. Histopathological examination of the excised lung tissue from both lobes revealed chronic inflammation with widespread hemorrhage and deposition of erythematous exudate within certain alveolar regions, accompanied by focal accumulation of eosinophils, aggregated mononuclear macrophages, and scattered multinucleated giant cell reactions in localized areas (Figure 2A). Significant necrotic material and eosinophil accumulation, along with Charcot-Leyden crystal formation, were observed in some bronchial lumens (Figure 2B). Both acid-fast staining, MTB culture, and TB-DNA testing yielded negative results, with no evidence of fungal hyphae detected.

Four months post-surgery, the follow-up chest CT scans revealed a newly solid mass in the lingual segment of the left upper lobe (Figure 1C). Subsequently, the patient presented to our institution. Upon review of the patient's medical history, we noted prior elevations in EOS and total serum IgE. Considering the diagnosis of PTB may have overshadowed the identification of potential comorbidities, we reassessed the patient's condition. The EOS count and total serum IgE level remained elevated. Sputum samples subjected to acid-fast staining and culture, as well as BALF subjected to mNGS, returned negative results. Additionally, serum IgG specific to *Aspergillus fumigatus* tested positive (2398 AU/mL), with a moderately sensitive *A.fumigatus*-specific IgE level (6.94 kUA/L, normal <0.35 kUA/L). Pulmonary function testing was normal, while the bronchial provocation test suggested a potential positive response.




Figure 2 Histopathological examination of the resection specimen showing chronic inflammation. **(A)** Marked infiltration of eosinophils, accumulation of mononuclear macrophages, and a multinucleated giant cell reaction, highlighting the inflammatory response (Hematoxylin and Eosin stain, $\times 200$). **(B)** Significant necrotic material and eosinophil accumulation within some bronchial lumens, with the presence of Charcot-Leyden crystals (highlighted by the red arrow), indicating an ongoing inflammatory process (Hematoxylin and Eosin stain, $\times 400$).

Considering all findings, the patient met the criteria outlined by the International Society for Human and Animal Mycology (ISHAM) for ABPA.⁴ Then she received itraconazole therapy for 12 weeks, during which no changes were observed in the lesion. Subsequently, oral corticosteroid therapy was initiated at an initial dose of 30mg qd, and tapered to 20mg qd after two weeks. After six weeks of steroid treatment, a follow-up chest CT scan revealed obvious absorption of the lesion (Figure 1D), along with gradual reductions in serum total IgE and EOS levels. Currently, the patient continues on a maintenance dose of prednisone 5 mg qd, with regular outpatient visits and plans for gradual medication discontinuation.

Discussion

To our knowledge, this is the second reported case of asymptomatic ABPA coexisting with active PTB. Min et al previously reported a similar case.⁵ However, unlike our identification of MTB through molecular analysis of bronchoalveolar lavage fluid, they observed both the typical pathological features of ABPA and PTB in the same lung lobe. The association between ABPA and PTB also remains a fascinating area of inquiry. On one hand, bronchial inflammation following tuberculosis infection, along with pulmonary scar cavity formation and bronchiectasis, creates a conducive environment for fungal colonization, thus predisposing individuals with a history of tuberculosis to develop *Aspergillus*-related pulmonary diseases,⁶ including ABPA in some cases. On the other hand, due to similar clinical features and

radiological manifestations, such as fleeting opacities, central bronchiectasis, mucus plugging, and centrilobular nodules (with a tree-in-bud appearance), patients with ABPA are often misdiagnosed with pulmonary tuberculosis and may receive prolonged anti-tuberculosis therapy, particularly in regions with high prevalence of tuberculosis.⁷

Additionally, some active tuberculosis patients experience symptoms such as dyspnea, wheezing, cough, and sputum production shortly after anti-tuberculosis treatment, leading to a diagnosis of ABPA upon reevaluation.⁸ It is conjectured that this could be linked to the suppression of the CD4⁺/Th1 immune response following anti-tuberculosis therapy, consequently favoring the Th2 type of response associated with asthma development and potentially ABPA.^{6,9,10} However, this mechanism has not been thoroughly investigated. As for why not every patient develops ABPA, this may be linked to genetic susceptibility.¹¹ Notably, this patient has exhibited a high Th2 type of immune response before anti-tuberculosis treatment. Previous reports have documented the potential coexistence of ABPA and active PTB within the same patient, and the confirmation of tuberculosis presence ultimately depended on pathological biopsy or Xpert MTB/RIF analysis.¹² In this case, the presence of *Mycobacterium tuberculosis* was confirmed through mNGS and Xpert MTB/RIF analysis, with subsequent lesion absorption post-anti-tuberculosis therapy further validating it.

Conclusion

In conclusion, the presence of PTB and ABPA probably exhibits temporal and spatial overlap. This emphasizes the importance of employing comprehensive diagnostic approaches, including pathological biopsy, Xpert MTB/RIF analysis, or mNGS for MTB detection. Additionally, before initiating glucocorticoid therapy for ABPA, particularly in patients from tuberculosis-endemic regions, meticulous assessment and exclusion of PTB are essential.

Abbreviations

RIF, Rifampicin; RPT, Rifapentine; INH, Isoniazid; EMB, Ethambutol; PZA, Pyrazinamide.

Acknowledgments

We would like to acknowledge the patient and his family who gave informed consent for this publication. No Institutional approval was required for publication of this case report.

Funding

This work was supported by 1.3.5 project for disciplines of excellence Clinical Research Incubation Project, West China Hospital, Sichuan University [grant number 2019HXFH008].

Disclosure

The authors report no conflicts of interest in this work.

References

- Agarwal R. Allergic bronchopulmonary aspergillosis. *Chest*. 2009;135(3):805–826. doi:10.1378/chest.08-2586
- Yanase K, Nakamura M, Toyoda T, et al. A case of allergic bronchopulmonary aspergillosis following active pulmonary tuberculosis. *Jpn J Allergol*. 1996;45(11):1181–1184. doi:10.15036/arugi.45.1181
- Ray A. Prevalence of allergic bronchopulmonary aspergillosis in post-tuberculosis lung disease patients presenting to a tertiary referral centre. *CHEST*. 2023;164(4):A45. doi:10.1016/j.chest.2023.07.088
- Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. *Clin Exp Allergy J Br Soc Allergy Clin Immunol*. 2013;43(8):850–873. doi:10.1111/cea.12141
- Min KH, Park SJ, Kim SR, et al. Coexistence of allergic bronchopulmonary aspergillosis and active pulmonary tuberculosis. *Am J Respir Crit Care Med*. 2011;183(1):137–139. doi:10.1164/ajrcm.183.1.137
- Agarwal R, Singh N, Aggarwal AN. An unusual association between mycobacterium tuberculosis and aspergillus fumigatus. *Monaldi Arch Chest Dis Arch Monaldi Mal Torace*. 2008;69(1):32–34. doi:10.4081/monaldi.2008.409
- Ekeng BE, Davies AA, Osaigbovo II, Warris A, Oladele RO, Denning DW. Pulmonary and extrapulmonary manifestations of fungal infections misdiagnosed as tuberculosis: the need for prompt diagnosis and management. *J Fungi Basel Switz*. 2022;8(5):460. doi:10.3390/jof8050460
- Boz AB, Celmeli F, Arslan AG, Cilli A, Ogus C, Ozdemir T. A case of allergic bronchopulmonary aspergillosis following active pulmonary tuberculosis. *Pediatr Pulmonol*. 2009;44(1):86–89. doi:10.1002/ppul.20934
- Shankar J, Thakur R, Clemons KV, Stevens DA. Interplay of cytokines and chemokines in aspergillosis. *J Fungi Basel Switz*. 2024;10(4):251. doi:10.3390/jof10040251

10. Gupta M, Roshan R, Chhabra S. Allergic bronchopulmonary aspergillosis without asthma complicating pulmonary tuberculosis. *Lung India*. 2012;29(3):286. doi:10.4103/0970-2113.99122
11. Gibson PG. Allergic bronchopulmonary aspergillosis. *Semin Respir Crit Care Med*. 2006;27(2):185–191. doi:10.1055/s-2006-939521
12. Purohit S, Joshee V. A rare case of coexistence of allergic bronchopulmonary aspergillosis (ABPA) and active pulmonary tuberculosis- role of CBNAAT in ABPA evaluation. *Indian J Tuberc*. 2019;66(3):418–419. doi:10.1016/j.ijtb.2019.01.004

Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress
Taylor & Francis Group